- Toxicology and Advanced Nanoscience in Lipid Nanoparticle mRNA-Based Therapies
-
Stars at Night Ballroom B2‚ Convention Center
Chair: Herve Lebrec, HL Toxicology and Preclinical Services
Co-Chair: Shon Green, Zelig Therapeutics
Primary Endorser: Biotechnology Specialty Section
Endorser(s): Nanoscience and Advanced Materials Specialty SectionLipid nanoparticle (LNP)–formulated messenger RNA (mRNA)therapeutics have rapidly emerged as a versatile platform for in vivo delivery of genetic payloads, enabling protein replacement, genome editing, gene silencing, and cell engineering applications. Building on the clinical success of mRNA-based vaccines, the field is expanding toward more complex indications, including oncology, rare diseases, and in vivo generation of engineered immune cells. The parallel development of well-structured toxicological assessments in vivo or in New Approach Methodologies (NAMs) can foster scientific discoveries to cure diseases. As these modalities evolve, so do the scientific and regulatory challenges associated with their development. This session will provide a comprehensive overview of LNP–mRNA drugs, beginning with an introduction to the diversity of modalities, including protein replacement, and delivery of genetic or epigenetic editors. Particular emphasis will be placed on how LNP composition(e.g., cationic or ionizable lipids, PEG-lipids), mRNA design (e.g., nucleotide modifications, sequence optimization, capping approach), LNP targeting (passive vs active) and route of administration influence pharmacokinetics, biodistribution, and pharmacodynamic outcomes. A central focus of the session will be the nonclinical safety assessment of LNP–mRNA therapeutics. Speakers will discuss key toxicological considerations, including innate immune activation, reactogenicity, complement activation-related pseudo-allergy (CARPA), hepatic and splenic accumulation, novel excipient safety assessment, mRNA immunogenicity, off target assessment for genome editors, and the implications of repeat dosing in the context of anti-PEG antibodies and adaptive immune responses. The relevance and limitations of animal models—particularly rodents and nonhuman primates—for predicting human safety will be critically evaluated, along with emerging approaches to improve translational risk assessment. Similarly, complexities associated with human targeting ligands that are not cross-reactive with NHPs will be discussed, weighing the limitations of surrogate ligands and humanized rodent models for nonclinical safety assessment. In addition, the session will address platform-specific challenges such as off-target protein expression, durability of expression, and the safety considerations associated with in vivo delivery of genome editing systems or immune-modulating payloads. Case studies and recent advances will be presented to illustrate how nonclinical strategies are being adapted to support IND-enabling programs for these rapidly evolving therapies. Presenters will share their experience with Regulatory expectations.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
